Session 1 : Controversies in Prostate Cancer Diagnosis
- PSMA-PET Controversies in Early Diagnosis of Prostate Cancer
- PSMA-PET Assessment of mCSPC Patient Population
- PSMA-PET in m0CRPC Patient Population
- How accurate is the PSMA-PET?
- Question 1: False positive and false negative with PSMA-PET
- Question 2: Alternatives to PSMA-PET imaging
- Question 3: The accuracy of imaging results depends on the tracer used
- Question 4: Will PSMA-PET be used for screening?
- Question 5: Standardisation of imaging procedures and results reporting among PSMA-PET testing centres.
- Future of Diagnosis: What is the Prostate Cancer Diagnosing Modality 5 years from now?
Session 2 : Controversies in Prostate Cancer Treatment
- TITAN
- Question 1: A review of the TITAN Trial: Will ADT continue to remain the standard of care in mCSPC? How do we select an NHT given that there are no head-to-head trials?
- Question 2: Post hoc Analysis of TITAN: Apalutamide with Prior Docetaxel Treatment
- Question 3: High volume vs Low volume: Do we need to look at disease volume when treating disease?
- Question 4: Improved Survival for mCSPC Patients
- SPARTAN
- PSA
- Question 1: What would be a pragmatic way to keep an eye on other parameters (outside of PSA use) in terms of monitoring disease response?
- Question 2: Is PSA monitoring important and at what intervals do you check the PSA levels?
- Question 3: What happens if after treatment initiation (APA for mCSPC), PSA declines less than 50% from baseline, what would you recommend? Do we immediately change treatment?
- Doublet vs Triplet Therapy
- Question 1: ARASENS and PEACE Study
- Question 2: Patient Selection for Triplet Therapy: Which type of patients?
- Question 3: Would you be concerned about the safety of ARASENS study?
- Question 4: Why does the darolutamide arm demonstrate hypertension cases twice that of placebo arm?
- Question 5: PEACE-1 Study
- Question 6: Can we speculate what results we would expect with APA+ADT+Docetaxel?
- Question 7: How will ARASENS and PEACE-1 impact treatment in mCSPC moving forward? Any specific group of patients that you think will benefit?
- Question 8: In terms of clinical tolerance (e.g. tiredness, various side effects, etc.), are they a lot more with triplet therapies vs docetaxel alone or AR pathway alone?
- Question 9: Any experience using Darolutamide + ADT alone in mCSPC?
- Others
- Question 1: How often do you subject your patients to imaging once patients have started treatment on ADT and NHT?
- Question 2: Genomic Profiling – If patients have BRCA mutation and de novo metastatic disease, what is considered the best front-line treatment because they don’t respond very well to NHT and should we wait until they progress to CR before adding on AR inhibitors /other agents or add AR inhibitors after chemotherapy?
